| 29.58 -0.2 (-0.67%) | 02-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 39.59 | 1-year : | 46.24 |
| Resists | First : | 33.9 | Second : | 39.59 |
| Pivot price | 28.43  |
|||
| Supports | First : | 25.21 | Second : | 19.85 |
| MAs | MA(5) : | 30.77 |
MA(20) : | 27.6 |
| MA(100) : | 21.1 |
MA(250) : | 10.44 |
|
| MACD | MACD : | 1.6 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 77.7 |
D(3) : | 80.9 |
| RSI | RSI(14): 56.8 |
|||
| 52-week | High : | 38.32 | Low : | 2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ GLTO ] has closed below upper band by 36.4%. Bollinger Bands are 10.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 32.57 - 32.76 | 32.76 - 32.93 |
| Low: | 29.22 - 29.41 | 29.41 - 29.58 |
| Close: | 29.51 - 29.81 | 29.81 - 30.08 |
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Tue, 17 Feb 2026
UBS Initiates Coverage of Galecto (GLTO) with Buy Recommendation - Nasdaq
Mon, 16 Feb 2026
Galecto (GLTO) Is Up 21.3% After $316 Million Equity Raise and New $150 Million Shelf Registration - Sahm
Thu, 12 Feb 2026
Galecto raises $316.3M as it develops blood cancer therapies - Stock Titan
Wed, 11 Feb 2026
Galecto Prices $275 Mln Public Offering At $19 Per Share, Stock Down - Nasdaq
Wed, 11 Feb 2026
Galecto, Inc. Announces Pricing of $275 Million Underwritten Public Offering of Common Stock - Quiver Quantitative
Mon, 08 Dec 2025
Galecto (GLTO) Rating Maintained by Guggenheim, Price Target Rai - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 1.9 (%) |
| Shares Short | 148 (K) |
| Shares Short P.Month | 172 (K) |
| EPS | -12.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.01 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -43.6 % |
| Return on Equity (ttm) | -109.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -2.5 |
| PEG Ratio | 0 |
| Price to Book value | 6.02 |
| Price to Sales | 0 |
| Price to Cash Flow | -149.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|